[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100513479":3},{"organization":4,"outcomesModule":7,"designInfo":34,"detailedDescription":33,"studyPopulation":37,"armGroups":33,"interventions":38,"overallOfficials":47,"centralContacts":52,"locations":61,"responsibleParty":81,"collaborators":33,"id":83,"slug":84,"hasResults":85,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":89,"eligibilityCriteria":90,"healthyVolunteers":85,"sex":91,"minAge":33,"maxAge":33,"enrollmentInfo":92,"targetDuration":95,"studyType":96,"phases":33,"briefSummary":97,"conditions":98,"keywords":33,"overallStatus":64,"whyStopped":33,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":113},{"fullName":5,"class":6},"PAVmed Inc.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":33},[9],{"measure":10,"description":11,"timeFrame":12},"Subsequent Clinical Management Following EsoGuard Testing","Proportion of subjects who undergo a clinically relevant management action following receipt of an EsoGuard result, including referral for esophagogastroduodenoscopy (EGD), surveillance, therapeutic intervention, or other physician-directed management. Clinical management decisions are collected as part of routine clinical care.","Up to 12 months following EsoGuard testing",[14,17,20,23,27,30],{"measure":15,"description":16,"timeFrame":12},"Endoscopic Confirmation of Barrett's Esophagus and\u002For Esophageal Neoplasia","Proportion of subjects with a completed EGD and pathology assessment confirming Barrett's esophagus (BE), dysplasia, esophageal adenocarcinoma (EAC), or other relevant esophageal findings following EsoGuard testing.",{"measure":18,"description":19,"timeFrame":12},"Disease Stage at Endoscopic Diagnosis","Histologic and\u002For clinical stage of Barrett's esophagus, dysplasia, or esophageal neoplasia identified during clinically indicated endoscopic evaluation following EsoGuard testing.",{"measure":21,"description":22,"timeFrame":12},"Therapeutic Interventions Following EsoGuard Testing","Proportion of subjects who undergo therapeutic intervention for BE, dysplasia, or EAC, including endoscopic eradication therapy, surgical intervention, pharmacologic treatment, or other standard-of-care management.",{"measure":24,"description":25,"timeFrame":26},"Surveillance Utilization Following EsoGuard Testing","Proportion of subjects who undergo follow-up surveillance procedures or monitoring for BE\u002FEAC according to routine clinical practice.","Up to 24 months following EsoGuard testing",{"measure":28,"description":29,"timeFrame":26},"Incident Detection of Barrett's Esophagus or Esophageal Adenocarcinoma","Number and proportion of subjects initially considered negative for BE\u002FEAC who subsequently receive a diagnosis of BE, dysplasia, or EAC during follow-up.",{"measure":31,"description":32,"timeFrame":26},"Disease Progression or Resolution","Among subjects with identified esophageal disease, assessment of disease progression, stability, or resolution based on available endoscopic, histologic, and clinical follow-up data.",null,{"allocation":33,"interventionModel":33,"interventionModelDescription":33,"primaryPurpose":33,"observationalModel":35,"timePerspective":36,"maskingInfo":33},"COHORT","PROSPECTIVE","Subjects who have recently undergone or are scheduled to undergo EsoCheck administration (as prescribed by a licensed healthcare provider) will be invited to participate in the optional EsoGuard Registry.",[39,43],{"type":40,"name":41,"description":42,"armGroupLabels":33,"otherNames":33},"DEVICE","EsoCheck®","EsoCheck® (EC) is an FDA 510(k) cleared device that is indicated for use in the collection and retrieval of surface cells of the esophagus in the general population 12 years of age and older.",{"type":44,"name":45,"description":46,"armGroupLabels":33,"otherNames":33},"DIAGNOSTIC_TEST","EsoGuard®","EsoGuard® is a DNA assay which examines for the presence of cytosine methylation at 31 different genomic locations on the vimentin (VIM) and Cyclin-A1 (CCNA1) genes. Using EsoCheck and EsoGuard in combination may offer an accurate, lower cost, non-invasive, approach to screen for Barrett's Esophagus (BE) with and without dysplasia, and for esophageal adenocarcinoma (EAC).",[48],{"name":49,"affiliation":50,"role":51},"Victoria Lee, MD","Lucid Diagnostics","STUDY_CHAIR",[53,58],{"name":54,"role":55,"phone":56,"phoneExt":33,"email":57},"Study Project Manager","CONTACT","917-813-1828","axr@pavmed.com",{"name":59,"role":55,"phone":33,"phoneExt":33,"email":60},"Sr. Director","gxl@pavmed.com",[62],{"facility":63,"status":64,"city":65,"state":66,"zip":67,"country":68,"countryCode":69,"cosmosGeoPoint":70,"geoPoint":75,"contacts":76},"LUCID DX","RECRUITING","Lake Forest","California","92630","United States","US",{"type":71,"coordinates":72},"Point",[73,74],-117.68922,33.64697,{"lat":74,"lon":73},[77],{"name":78,"role":55,"phone":79,"phoneExt":33,"email":80},"Lucid Dx Labs","888-582-4339","info@LucidDx.com",{"type":82,"investigatorFullName":33,"investigatorTitle":33,"investigatorAffiliation":33,"oldNameTitle":33,"oldOrganization":33},"SPONSOR","100513479","lucid-registry-study-100513479",false,"NCT05965999","Lucid Registry Study","A Multicenter, Prospective, Open-Label Registry Study of the Utilization of EsoGuard, on Samples Collected Using EsoCheck, in an At-Risk Population Undergoing Standard of Care Screening for, and Management of, Previously Undiagnosed Barrett's Esophagus and\u002For Esophageal Adenocarcinoma","Lucid Registry","Inclusion Criteria:\n\n1. Individuals in whom a healthcare provider has made the independent clinical decision to screen for BE\u002FEAC (based on assessment of elevated disease risk) using EsoGuard for analysis of cell samples collected with EsoCheck\n2. Provided written informed consent for prospective registry participation\u002Fdata collection\n\nExclusion Criteria:\n\n1. Inability to provide written informed consent\n2. Subjects who fall outside the eligible population defined by the EsoCheck device Instructions For Use (IFU)","ALL",{"count":93,"type":94},8000,"ESTIMATED","10 Years","OBSERVATIONAL","This is a multicenter, prospective, observational study designed to capture a limited set of data consisting of diagnostic test results and clinical management information on subjects who undergo EC\u002FEG to assess for the presence of BE\u002FEAC. Once sufficient time has elapsed for EsoGuard results to be available, as well as for any subsequent clinical evaluation to have been performed (e.g., upper endoscopy and any initial therapeutic management), study staff will obtain the desired information and record it in an electronic data collection (EDC) system, pertaining to subject demographics, pertinent medical history, and risk factors for BE or EAC as well as (1) information about the EsoCheck cell collection procedure and patient tolerance, (2) EsoGuard test result; (3) initial clinical management including upper endoscopy, if performed, and diagnosis (as determined by the endoscopist and the pathologist assessing any biopsies taken.\n\nFor subjects endoscopically confirmed with intestinal metaplasia, dysplasia, or cancer, the registry will collect additional clinical management and\u002For a therapeutic procedure(s) performed and other mid- to long-term outcomes.\n\nFor subjects who are negative for BE\u002FEAC via EsoGuard or negative for BE\u002FEAC via EGD will be offered the option of longer-term follow-up in the form of intermittent wellness checks.\n\nThe time point for collecting such information shall be fluid, depending on the time course of care provided subsequent to the EsoGuard result being available. Subject participation duration is dependent on EsoGuard results, physician referral, EGD results (if referred) and participation in long-term follow-up. If EG results are negative and subject is not referred for an EGD, participation could last 1 month. If a subject is confirmed with BE\u002FEAC, participation may continue beyond this minimum for an indefinite period, with no predetermined maximum duration.",[99,100,101,102],"Barrett Esophagus","Esophageal Adenocarcinoma","Barretts Esophagus With Dysplasia","Barrett's Esophagus Without Dysplasia","2026-09-23",{"date":105,"type":106},"2026-09-28","ACTUAL",{"date":108,"type":106},"2023-04-11",{"date":110,"type":94},"2027-12-31",{"name":112,"class":6},"Lucid Diagnostics, Inc.",1]